Enliven Therapeutics, Inc (ELVN) Misses Q4 EPS by 2c

Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q4 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.

You May Also Be Interested In

• Jersey Mike's Subs (JMKE) PT Raised to $30 at Tigress Financial Partners
• UBS Reiterates Neutral Rating on salesforce.com (CRM) Ahead of Dreamforce Conference
• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms